Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pre-Operative Chemoradiation and Post-Operative Tetrathiomolybdate in Esophageal Carcinoma
NCT00176800Phase 2Completed
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Nov 2001
- Primary completion
- Feb 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tetrathiomolybdate in esophageal carcinoma, sponsored by University of Michigan Rogel Cancer Center. Primary endpoint: Recurrence Free Survival at 8 years. Started Nov 2001; status: completed.
02
Drugs
tetrathiomolybdate
03
Conditions
esophageal carcinoma
Beyond the preview
Go deeper on NCT00176800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00176800.